MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1

  • Authors:
    • Yan-Ling Chen
    • Zi-Mu Zhang
    • Xiao-Lu Li
    • Yan-Fang Tao
    • Shui-Yan Wu
    • Fang Fang
    • Yi Xie
    • Xin-Mei Liao
    • Gen Li
    • Di Wu
    • Hai-Rong Wang
    • Ran Zuo
    • Hai-Bo Cao
    • Jing-Jing Pan
    • Juan-Juan Yu
    • Zheng Zhang
    • Xin-Ran Chu
    • Yong-Ping Zhang
    • Chen-Xi Feng
    • Jian-Wei Wang
    • Jun Lu
    • Shao-Yan Hu
    • Zhi-Heng Li
    • Jian Pan
  • View Affiliations

  • Published online on: October 18, 2021     https://doi.org/10.3892/ol.2021.13099
  • Article Number: 838
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neuroblastoma (NB) is a common pediatric malignancy associated with poor outcomes. Recent studies have shown that murine double minute2 homolog (MDM2) protein inhibitors are promising anticancer agents. MI‑773 is a novel and specific antagonist of MDM2, however, the molecular mechanism of its anti‑NB activity remains unclear. NB cell viability was measured by Cell Counting Kit‑8 assay following MI‑773 treatment. Cell cycle progression was analyzed using PI staining and apoptosis was assessed using Annexin V/PI staining. The molecular mechanisms by which MI‑773 exerted its effects were investigated using a microarray. The results showed that disturbance of the MDM2/p53 axis by MI‑773 resulted in potent suppression of proliferation, induction of apoptosis and cell cycle arrest in NB cells. In addition, microarray analysis showed that MI‑773 led to significant downregulation of genes involved in the G2/M phase checkpoint and upregulation of hallmark gene associated with the p53 pathway. Meanwhile, knockdown of insulinoma‑associated 1 decreased proliferation and increased apoptosis of NB cells. In conclusion, the present study demonstrated that MI‑773 exhibited high selectivity and blockade affinity for the interaction between MDM2 and TP53 and may serve as a novel strategy for the treatment of NB.
View References

Related Articles

Journal Cover

December-2021
Volume 22 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Zhang Z, Li X, Tao Y, Wu S, Fang F, Xie Y, Liao X, Li G, Wu D, Wu D, et al: MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1. Oncol Lett 22: 838, 2021
APA
Chen, Y., Zhang, Z., Li, X., Tao, Y., Wu, S., Fang, F. ... Pan, J. (2021). MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1. Oncology Letters, 22, 838. https://doi.org/10.3892/ol.2021.13099
MLA
Chen, Y., Zhang, Z., Li, X., Tao, Y., Wu, S., Fang, F., Xie, Y., Liao, X., Li, G., Wu, D., Wang, H., Zuo, R., Cao, H., Pan, J., Yu, J., Zhang, Z., Chu, X., Zhang, Y., Feng, C., Wang, J., Lu, J., Hu, S., Li, Z., Pan, J."MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1". Oncology Letters 22.6 (2021): 838.
Chicago
Chen, Y., Zhang, Z., Li, X., Tao, Y., Wu, S., Fang, F., Xie, Y., Liao, X., Li, G., Wu, D., Wang, H., Zuo, R., Cao, H., Pan, J., Yu, J., Zhang, Z., Chu, X., Zhang, Y., Feng, C., Wang, J., Lu, J., Hu, S., Li, Z., Pan, J."MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1". Oncology Letters 22, no. 6 (2021): 838. https://doi.org/10.3892/ol.2021.13099